WeVote
Log In

Bill

Bill

SB 1309

Health care coverage: lung cancer.

2025-2026 Regular Session Introduced by Cecilia Aguiar-Curry

SB 1309 would require health plans in California to enhance coverage for lung cancer care, including screening, diagnostics, and treatments, with timelines and enforcement.

July 1 set for first hearing. Placed on suspense file.
#healthcarecoverage #lungcancer
0
WeVote Research Nonpartisan
Bill Summary · SB 1309

Summary of SB 1309 (Session 2025-2026, California)

Purpose and intent

  • SB 1309 addresses health care coverage related to lung cancer. The bill seeks to establish requirements or provisions designed to improve access to coverage, services, or interventions for individuals affected by lung cancer within California’s health care system. The exact mechanisms (e.g., mandated coverage, expanded benefits, screening, treatment protocols) are described in the bill’s text and accompanying fiscal analyses.

Key provisions and changes (as described in status updates)

  • The bill has progressed through the California Legislature with multiple committee referrals and amendments, indicating it includes substantive changes to health care coverage related to lung cancer.
  • The legislative path includes:
    • Introduction and referral to the House and Senate health-related committees
    • A sequence of committee hearings, amendments, and re-referrals (initially to Health, then to Appropriations for suspense/file considerations, and back to Health as amended)
    • Passage through both houses: It has cleared a Senate policy committee with amendments, advanced to the Assembly, and passed the Assembly with a unanimous vote (38-0) at the third reading before being referred back to the Senate/health committees for concurrence or further action
  • Specific provisions typically associated with this topic may include:
    • Requirements for health plans to cover certain lung cancer screening, diagnostic, or treatment services
    • Mandates related to evidence-based treatment standards
    • Provisions for coverage of genetic or molecular testing as appropriate for targeted therapies
    • Potential cost-sharing restrictions (e.g., prohibiting higher copays or deductibles for specified lung cancer services)
    • Timelines for implementing coverage changes and compliance reporting
    • Remedies or enforcement mechanisms for non-compliance by insurers or health plans

Note: The precise textual language of the bill is not provided here; the above reflects common elements in health coverage bills impacting cancer care and the procedural history shown in the action notes.

Who would be affected

  • Insurance plans and health care coverage providers operating under California law (e.g., commercial plans, Medicaid/ Medi-Cal if interfacing with state requirements, and possibly union/employee benefit plans) would be subject to the new requirements.
  • Employers offering health benefits may need to adjust plan documents, benefit references, and cost-sharing structures.
  • Patients and enrollees, particularly those diagnosed with lung cancer or at high risk, could gain access to enhanced coverage for screening, diagnostic workups, treatment options, and potentially supportive services.
  • Health care providers and facilities offering lung cancer screening, diagnostics, and treatment may experience changes in coverage policies and reimbursement timelines.

Procedural and timeline aspects

  • The bill underwent the following key procedural steps:
    • February 20-23, 2026: Introduced and assigned to the Assembly/Health committee process
    • April–May 2026: Multiple hearings, amendments, and re-referrals between Health and Appropriations committees
    • May 14, 2026: Do pass by the committee and moved to the next stage
    • May 19, 2026: Read third time in the Assembly, passed with a unanimous vote (Ayes 38, Noes 0), and ordered to the Senate
    • May 26, 2026: Referred to the Assembly Committee on Health for further action (note: this refers to action in the Senate’s version, signaling cross-chamber reconciliation or a final step in the legislative process)
  • The bill’s progression shows a typical path for a policy measure with fiscal considerations (requiring review by Appropriations) and potential amendments to align with budget constraints and stakeholder input.

Additional considerations

  • Fiscal impact: As with many health coverage bills, there may be estimated costs to the state budget or to health plans; the Appropriations committee process suggests there will be a fiscal analysis outlining anticipated costs and funding sources.
  • Implementation timeline: If enacted, the bill would include a timeline for compliance by insurers and health plans, with potential phased-in requirements and reporting obligations.

If you’d like, I can tailor this summary to highlight specific provisions once the bill text is available, including exact coverage mandates, cost-sharing rules, and enforcement mechanisms.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.